Iconovo
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ideongatan 3b, Lund, Skane, 22370, Swede...Phone Number
+46 462756777Website
www.iconovo.seRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Iconovo
Iconovo is a leading expert in inhalation medicine, specializing in the development of inhalation products, inhaler devices, and dry powder formulations. The company partners with pharmaceutical firms to provide end-to-end product development, leveraging its patented inhaler technology and drug formulation expertise. While primarily focused on respiratory care, Iconovo is expanding its capabilities to explore other therapeutic areas where inhalation can enhance drug delivery. Their integrated development process combines engineering and pharmaceutical knowledge to create customized inhalers and formulations for clients.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Iconovo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Iconovo launches new products
Check if Iconovo has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Iconovo recently announced quarterly report
Iconovo, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Iconovo had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Iconovo has new funding data
Congratulate Masked Content for being promoted to Masked Content at Iconovo
Check out if Iconovo is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Iconovo as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Iconovo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Iconovo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Iconovo.
Iconovo financials insights
Gather financial insights about Iconovo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$1M
2017
Private Equity
$2.6M
Iconovo Tech Stack
A closer look at the technologies used by Iconovo
Iconovo News & Media
Arcede Pharma and Iconovo take the next step in the development of a new treatment for COPD
Arcede Pharma, which develops inhalation treatments for COPD and severe asthma, and Iconovo AB (publ), which develops complete inhalation products for a global market, announce today that the collaborative project around Arcede's drug candidate RCD405 is progressing with good results. The next step in the project is a technical stability study before the drug candidate can be tested clinically. The project supported by SweLife is part of the previously communicated collaboration between Arcede PBioStock: Iconovo on the way to profitability
Iconovo, a leading developer of inhalation products, consolidates its financial targets for 2027 – revenues of 250 MSEK with an EBIDTA margin of 50 percent. Approximately 85 percent of the revenue is expected to come from projects that have already been initiated. In addition, the company expects to achieve profitability during one quarter as early as next year and 2025, as well as full-year profitability in 2026. BioStock contacted CEO Johan Wäborg to gain aBioStock: Iconovo launch Accelerator Program
Iconovo has chosen to launch an Accelerator Program to facilitate the opportunities for the company’s customers to obtain EU funding for the development of novel pharmaceuticals. The programme is made possible through a collaboration with the consulting company Argentum, which specialises in structuring and managing application processes for EU funding. BioStock contacted Måns Österberg, Director Alliance Management at Iconovo, to learn more about the initiative. Read the full article at biostocIconovo receives $883,800 grant from the Bill & Melinda Gates Foundation - PharmaTimes
Funding will develop inhaled therapies using ICOone Nasal in preparation for the next pandemic - News - PharmaTimes
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Iconovo
Sign Up For FreeTo access detailed company insights
Iconovo is a leading expert in inhalation medicine, specializing in the development of inhalation products, inhaler devices, and dry powder formulations. The company partners with pharmaceutical firms to provide end-to-end product development, leveraging its patented inhaler technology and drug formulation expertise. While primarily focused on resp... Read More
